PMA
P870043: SPECTRAPROBE-PLR MODEL 900 OPTILASE CONTACT LASER
FDA PMA · DEVICE, ANGIOPLASTY, LASER, CORONARY · Trimedyne, Inc.
Key facts
| PMA number | P870043 |
|---|---|
| Trade name | SPECTRAPROBE-PLR MODEL 900 OPTILASE CONTACT LASER |
| Generic name | DEVICE, ANGIOPLASTY, LASER, CORONARY |
| Applicant | Trimedyne, Inc. |
| Owner/operator | TRIMEDYNE, INC. |
| Product code | LPC |
| Approval date | Jun 30, 1988 |
| Docket number | 88M-0264 |
| Notice date | Aug 10, 1988 |
| Establishment registration | 1419951 |
| FEI number | 1419951 |
At a glance
- 10–99 Supplements
- Mar 17, 1994 Latest supplement decision
- Yes Withdrawn
- No Summary of safety and effectiveness on file
- 1–9 UDI device identifiers (GUDID)
- None MAUDE adverse event reports
- None Recall events
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA approvals
Premarket approval (PMA) is the FDA's most stringent review pathway, required for most Class III devices that support or sustain life or present a potentially unreasonable risk.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: